Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Varga

Showing results (151-160 of 297) with videos related to

Pageof 30
Sort By:
Seminars in Arthritis and Rheumatism|May 3, 2016
Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international surveyCamelia Frantz, Jérôme Avouac, Oliver Distler, et al.
The American Journal of Pathology|June 25, 2004
Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of sclerodermaGabriella Lakos, Shinsuke Takagawa, Shu-Jen Chen, et al.
JAMA Network Open|December 14, 2020
Lung Cancer Survival in Patients With Autoimmune DiseaseSaya Jacob, Kian Rahbari, Kyle Tegtmeyer, et al.
Clinical and Experimental Rheumatology|April 21, 2023
Mental health symptoms in scleroderma during COVID-19: a Scleroderma Patient-centred Intervention Network (SPIN) cohort longitudinal studyRichard S Henry, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Arthritis Research & Therapy|October 25, 2012
The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapyFeng Fang, Lei Liu, Yang Yang, et al.
ACR Open Rheumatology|July 19, 2022
Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled TrialShervin Assassi, Oliver Distler, Yannick Allanore, et al.
Scientific Reports|August 9, 2018
An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosisTakashi Yamashita, Katja Lakota, Takashi Taniguchi, et al.
JCI Insight|September 22, 2022
Deficiency of inhibitory TLR4 homolog RP105 exacerbates fibrosisWenxia Wang, Swarna Bale, Bharath Yalavarthi, et al.
Annals of the Rheumatic Diseases|March 22, 2013
A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responsesJun Wei, Hongyan Zhu, Kazuhiro Komura, et al.
Plos One|January 22, 2015
Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohortsMichael E Johnson, J Matthew Mahoney, Jaclyn Taroni, et al.
Pageof 30

Showing results (151-160 of 297) with videos related to

Sort By:
Pageof 30
Seminars in Arthritis and Rheumatism|May 3, 2016
Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international surveyCamelia Frantz, Jérôme Avouac, Oliver Distler, et al.
The American Journal of Pathology|June 25, 2004
Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of sclerodermaGabriella Lakos, Shinsuke Takagawa, Shu-Jen Chen, et al.
JAMA Network Open|December 14, 2020
Lung Cancer Survival in Patients With Autoimmune DiseaseSaya Jacob, Kian Rahbari, Kyle Tegtmeyer, et al.
Clinical and Experimental Rheumatology|April 21, 2023
Mental health symptoms in scleroderma during COVID-19: a Scleroderma Patient-centred Intervention Network (SPIN) cohort longitudinal studyRichard S Henry, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Arthritis Research & Therapy|October 25, 2012
The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapyFeng Fang, Lei Liu, Yang Yang, et al.
ACR Open Rheumatology|July 19, 2022
Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled TrialShervin Assassi, Oliver Distler, Yannick Allanore, et al.
Scientific Reports|August 9, 2018
An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosisTakashi Yamashita, Katja Lakota, Takashi Taniguchi, et al.
JCI Insight|September 22, 2022
Deficiency of inhibitory TLR4 homolog RP105 exacerbates fibrosisWenxia Wang, Swarna Bale, Bharath Yalavarthi, et al.
Annals of the Rheumatic Diseases|March 22, 2013
A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responsesJun Wei, Hongyan Zhu, Kazuhiro Komura, et al.
Plos One|January 22, 2015
Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohortsMichael E Johnson, J Matthew Mahoney, Jaclyn Taroni, et al.
Pageof 30